These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17448184)

  • 21. Evidence-based medicine: botulinum toxin A in migraine and tension-type headache.
    Göbel H; Heinze A; Heinze-Kuhn K; Jost WH
    J Neurol; 2001 Apr; 248 Suppl 1():34-8. PubMed ID: 11357239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin and the treatment of headache: A clinical review.
    Finkel AG
    Toxicon; 2015 Dec; 107(Pt A):114-9. PubMed ID: 26365919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Status on the use of botulinum toxin for headache disorders.
    Evers S
    Curr Opin Neurol; 2006 Jun; 19(3):310-5. PubMed ID: 16702841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria.
    Evers S; Rahmann A; Vollmer-Haase J; Husstedt IW
    Cephalalgia; 2002 Nov; 22(9):699-710. PubMed ID: 12421155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
    Luvisetto S; Gazerani P; Cianchetti C; Pavone F
    Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Botulinum toxin type A in headache treatment : Established and experimental indications].
    Gaul C; Holle-Lee D; Straube A
    Nervenarzt; 2016 Aug; 87(8):853-9. PubMed ID: 27300190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)].
    Lantéri-Minet M; Demarquay G; Alchaar H; Bonnin J; Cornet P; Douay X; Dousset V; Géraud G; Guillouf V; Navez M; Radat F; Radenne S; Revol A; Valade D; Donnet A
    Rev Neurol (Paris); 2014 Mar; 170(3):162-76. PubMed ID: 24594364
    [No Abstract]   [Full Text] [Related]  

  • 29. Practical management of headache.
    Aamodt AH; Bjørk MH; Alstadhaug KB; Eldøen G; Dueland AN; Poole T; Hagen K; Vetvik KG; Ofte HK; Sønnervik J; Kristoffersen ES; Winsvold BS; Lundqvist C; Sagabråten SO
    Tidsskr Nor Laegeforen; 2019 Apr; 139(7):. PubMed ID: 30969051
    [No Abstract]   [Full Text] [Related]  

  • 30. Epidemiology and management of medication-overuse headache in the general population.
    Russell MB
    Neurol Sci; 2019 May; 40(Suppl 1):23-26. PubMed ID: 30887240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States.
    Patil S; Willett O; Thompkins T; Hermann R; Ramanathan S; Cornett EM; Fox CJ; Kaye AD
    Curr Pain Headache Rep; 2016 Mar; 20(3):15. PubMed ID: 26879873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Botulinum toxin type a as a prophylactic treatment for chronic daily headache: time to conduct a large clinical trial in Taiwan?
    Liu HC
    J Chin Med Assoc; 2007 Dec; 70(12):519-20. PubMed ID: 18194891
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience.
    Farinelli I; Coloprisco G; De Filippis S; Martelletti P
    J Headache Pain; 2006 Dec; 7(6):407-12. PubMed ID: 17149565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study.
    Zhang H; Zhang H; Wei Y; Lian Y; Chen Y; Zheng Y
    Int J Neurosci; 2017 Apr; 127(4):285-290. PubMed ID: 27439999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Side-locked and side shifting primary headaches.
    Da Silva AN; Tepper SJ; Evans RW
    Headache; 2012; 52(7):1178-83. PubMed ID: 22724506
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of botulinum toxin type A in new daily persistent headache.
    Spears RC
    J Headache Pain; 2008 Dec; 9(6):405-6. PubMed ID: 18953487
    [No Abstract]   [Full Text] [Related]  

  • 37. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
    Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin type A: Exploring new indications.
    Brashear A
    Drugs Today (Barc); 2010 Sep; 46(9):671-82. PubMed ID: 20967299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
    J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug-resistant headache: is it the end?].
    Nater B; Dozier C
    Rev Med Suisse; 2012 May; 8(339):937-8, 940-1. PubMed ID: 22675824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.